Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Development of varicella vaccine.

Takahashi M, Asano Y, Kamiya H, Baba K, Ozaki T, Otsuka T, Yamanishi K.

J Infect Dis. 2008 Mar 1;197 Suppl 2:S41-4. doi: 10.1086/522132.

PMID:
18419406
2.

The safety profile of varicella vaccine: a 10-year review.

Galea SA, Sweet A, Beninger P, Steinberg SP, Larussa PS, Gershon AA, Sharrar RG.

J Infect Dis. 2008 Mar 1;197 Suppl 2:S165-9. doi: 10.1086/522125. Review.

PMID:
18419392
3.

The effect of vaccination on the epidemiology of varicella zoster virus.

Edmunds WJ, Brisson M.

J Infect. 2002 May;44(4):211-9. Review.

PMID:
12099726
4.

The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review.

Reynolds MA, Chaves SS, Harpaz R, Lopez AS, Seward JF.

J Infect Dis. 2008 Mar 1;197 Suppl 2:S224-7. doi: 10.1086/522162. Review.

PMID:
18419401
5.

[A live attenuated varicella vaccine].

Asano Y.

Uirusu. 2009 Dec;59(2):249-55. Review. Japanese.

6.

Consensus: varicella vaccination of healthy children--a challenge for Europe.

Rentier B, Gershon AA; European Working Group on Varicella.

Pediatr Infect Dis J. 2004 May;23(5):379-89. Review.

PMID:
15131459
7.

Current status and prospects of live varicella vaccine.

Takahashi M.

Vaccine. 1992;10(14):1007-14. Review.

PMID:
1335196
8.

Varicella zoster vaccines.

Creed R, Satyaprakash A, Ravanfar P.

Dermatol Ther. 2009 Mar-Apr;22(2):143-9. doi: 10.1111/j.1529-8019.2009.01226.x. Review.

PMID:
19335725
9.

Chickenpox.

Hambleton S.

Curr Opin Infect Dis. 2005 Jun;18(3):235-40. Review.

PMID:
15864101
10.

A review of the varicella vaccine in immunocompromised individuals.

Sartori AM.

Int J Infect Dis. 2004 Sep;8(5):259-70. Review.

11.
12.

Pathogenesis and current approaches to control of varicella-zoster virus infections.

Gershon AA, Gershon MD.

Clin Microbiol Rev. 2013 Oct;26(4):728-43. doi: 10.1128/CMR.00052-13. Review.

13.

Humoral and cell-mediated immune responses in children and adults after 1 and 2 doses of varicella vaccine.

Watson B.

J Infect Dis. 2008 Mar 1;197 Suppl 2:S143-6. doi: 10.1086/522130. Review.

PMID:
18419388
14.

Clinicopathologic understanding and control of varicella-zoster virus infection.

Asano Y.

Vaccine. 2008 Nov 25;26(50):6487-90. doi: 10.1016/j.vaccine.2008.08.004. Epub 2008 Aug 9. Review.

PMID:
18694794
15.

Development of a live varicella vaccine--past and future.

Takahashi M.

Jpn J Infect Dis. 2000 Apr;53(2):47-55. Review.

PMID:
10871914
16.

Immune responses to varicella-zoster virus.

Arvin AM.

Infect Dis Clin North Am. 1996 Sep;10(3):529-70. Review.

PMID:
8856351
17.

Molecular and therapeutic aspects of varicella-zoster virus infection.

Quinlivan M, Breuer J.

Expert Rev Mol Med. 2005 Aug 10;7(15):1-24. Review.

PMID:
16098235
18.

[Varicella vaccination: who should be vaccinated these days?].

Hügle B, Suchowerskyj P, Schuster V.

MMW Fortschr Med. 2005 Feb 24;147(8):31-2, 34-5. Review. German.

PMID:
18441563
19.

Live attenuated varicella vaccine.

Arvin AM, Gershon AA.

Annu Rev Microbiol. 1996;50:59-100. Review.

PMID:
8905076
20.

The varicella vaccine. Clinical trials in immunocompromised individuals.

Gershon AA, LaRussa P, Steinberg S.

Infect Dis Clin North Am. 1996 Sep;10(3):583-94. Review.

PMID:
8856353

Supplemental Content

Support Center